Dicerna Pharmaceutic (DRNA) 3.45 $DRNA Dicerna to

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 2:15 AM

Dicerna Pharmaceutic (DRNA) 3.45 $DRNA

Dicerna to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference. The presentation will take place on Thursday, June 9, 2016 at 1:30 p.m. ET at the Grand Hyatt in New York City.
DRNA: 3.45 (-0.21)

Dicerna Pharmaceuticals (DRNA) Jumps: Stock Rises 8.7%
Zacks Equity Research - Zacks Investment Research - Mon May 23, 7:15AM CDT
Dicerna Pharmaceuticals, Inc. (DRNA) shares rose almost 9% in the last trading session.
DRNA: 3.45 (-0.21), ANIP: 52.05 (-1.64)

Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 (PH1)
BusinessWire - Fri May 13, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ

RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has dosed the first patient in its DCR-PH1-101 trial, the first Phase 1 clinical trial of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1). A severe, rare, inherited disorder of the liver, PH1 often results in kidney failure, and there are no approved therapies for the disease.
DRNA: 3.45 (-0.21)

Dicerna Reports Potent Preclinical Activity with GalNAc-DsiRNA-EX Conjugates
BusinessWire - Wed May 11, 6:30AM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ

RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today will present updated preclinical data demonstrating the potency of its proprietary GalNAc-DsiRNA-EX Conjugate technology in enabling direct delivery of RNAi-based therapy to the liver via subcutaneous (SC) injection, with potential utility against multiple therapeutic targets. The presentation will take place at the 18th Annual TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Conference in Long Beach, Calif.
DRNA: 3.45 (-0.21)

Dicerna Reports First Quarter 2016 Financial and Operational Results
BusinessWire - Mon May 09, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq

RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported financial and operational results for the first quarter ended March 31, 2016.
DRNA: 3.45 (-0.21)

Dicerna to Report First Quarter 2016 Financial Results and Host Conference Call on May 9, 2016
BusinessWire - Mon May 02, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2016 financial results after market close on Monday, May 9, 2016.
DRNA: 3.45 (-0.21)

Dicerna Announces Appointment of John "Jack" Green as Chief Financial Officer
BusinessWire - Mon Apr 18, 3:05PM CDT
Dicerna Pharmaceuticals, Inc. (NASDAQ

RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced the appointment of John B. "Jack" Green as chief financial officer (CFO), effective immediately. Mr. Green has served as the Company's interim CFO since January 2016.
DRNA: 3.45 (-0.21)

Alnylam Begins Study for Primary Hyperoxaluria Type 1
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 3:45PM CST
Alnylam Pharmaceuticals (ALNY) announced that it has initiated a phase I/II study on ALN-GO1 for the treatment of primary hyperoxaluria type 1.
DRNA: 3.45 (-0.21), ALNY: 63.17 (-2.24), SNY: 39.41 (-1.45)

Dicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results
BusinessWire - Thu Mar 10, 3:00PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced financial and operational results for the quarter and full year ended December 31, 2015.
DRNA: 3.45 (-0.21)

Dicerna to Announce Fourth Quarter and Full Year 2015 Financial Results and Host Conference Call on March 10, 2016
BusinessWire - Fri Mar 04, 12:52PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, announced that the Company will release its fourth quarter and full year 2015 financial results after market close on Thursday, March 10, 2016.
DRNA: 3.45 (-0.21)

Dicerna to Present at Two March Conferences
BusinessWire - Wed Mar 02, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the following conferences:
DRNA: 3.45 (-0.21)

Multiple Myeloma (Kahler Disease) Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/dldvmh/multiple_myeloma) has announced the addition of the "Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Multiple Myeloma (Kahler Disease) Overview - Therapeutics Development - Pipeline Products for Multiple Myeloma (Kahler Disease) - Overview - Pipeline Products for Multiple Myeloma (Kahler Disease) - Comparative Analysis - Multiple Myeloma (Kahler Disease) - Therapeutics under Development by Companies - Multiple Myeloma (Kahler Disease) - Therapeutics under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Multiple Myeloma (Kahler Disease) - Products under Development by Companies - Multiple Myeloma (Kahler Disease) - Products under Investigation by Universities/Institutes - Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Companies Mentioned - Sample List - Anthera Pharmaceuticals Inc. - APIM Therapeutics AS - APO-T B.V. - Arcarios BV - BioLineRx, Ltd. - Biotest AG - Bluebird bio, Inc. - DC Prime B.V. - Dicerna Pharmaceuticals, Inc. - Eli Lilly and Company - Enceladus Pharmaceuticals BV - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - Immunomedics, Inc. - Immunomic Therapeutics, Inc. - Incyte Corporation - Inflection Biosciences Limited - Inventiva SAS - Jasco Pharmaceuticals, LLC. - NantKwest, Inc. - Nippon Kayaku Co., Ltd. - Nordic Nanovector ASA - OXIS International, Inc. - Panacela Labs, Inc. - Patrys Limited - Peptinov SAS - ProMIS Neurosciences Inc. - Quest PharmaTech Inc. - Rhizen Pharmaceuticals S.A. - Sphaera Pharma Pvt. Ltd. - Stemline Therapeutics, Inc. - Sumitomo Dainippon Pharma Co., Ltd. - Synta Pharmaceuticals Corp. - XTL Biopharmaceuticals Ltd. - Zyngenia, Inc. For more information visit http://www.researchandmarkets.com/research/dl...le_myeloma
IMMU: 3.05 (-0.08), DRNA: 3.45 (-0.21), INCY: 80.41 (-1.20), LLY: 73.95 (-0.48), STML: 7.50 (-0.53), SNTA: 0.35 (-0.01), ANTH: 3.40 (-0.12), EXEL: 7.38 (+0.01)

Dicerna to Present at the 2016 Leerink Partners Global Healthcare Conference
BusinessWire - Thu Feb 04, 7:00AM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational RNA interference therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present at the Leerink Partners 5th Annual Global Healthcare Conference. The presentation will take place at the Waldorf Astoria in New York City on Thursday, February 11th, 2016 at 11:35 a.m. ET.
DRNA: 3.45 (-0.21)

Dicerna Pharmaceuticals, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BusinessWire - Thu Dec 31, 3:27PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNA interference-based therapeutics targeting rare inherited diseases involving the liver and for cancers that are genetically defined, today announced that on December 31, 2015, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 115,000 shares of common stock to two new employees, with a grant date of December 31, 2015 (the "Q4 2015 Inducement Grants"

.
DRNA: 3.45 (-0.21)

Alnylam Submits Clinical Trial Application for ALN-GO1 in UK
Zacks Equity Research - Zacks Investment Research - Tue Dec 22, 2:50PM CST
Alnylam (ALNY) filed a CTA for ALN-GO1 with the UK Medicines and Healthcare products Regulatory Agency for the treatment of primary hyperoxaluria type 1.
DRNA: 3.45 (-0.21), ALNY: 63.17 (-2.24), ANIK: 49.16 (+0.24), SNY: 39.41 (-1.45)

Dicerna Updates Progress on the Development of DCR-MYC for the Treatment of Solid Tumors
BusinessWire - Mon Dec 21, 3:54PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ

RNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported continued progress in the clinical development of DCR-MYC, Dicerna's investigational Dicer substrate short interfering RNA (DsiRNA) therapeutic designed to silence MYC, an oncogene implicated in multiple tumor types. Dicerna plans to report proof-of-concept data for DCR-MYC in the second half of 2016 based on anticipated results from a Phase 1 clinical trial of DCR-MYC in patients with advanced solid tumors, multiple myeloma, or lymphoma, and a Phase 1b/2 trial in patients with hepatocellular carcinoma (HCC).
DRNA: 3.45 (-0.21)

Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 (PH1) in Healthy Volunteers
BusinessWire - Mon Dec 21, 3:10PM CST
--- Ongoing Observational Study Measures Biomarkers Implicated in the Pathogenesis of PH1 -
DRNA: 3.45 (-0.21)

Dicerna Announces Addition to NASDAQ Biotechnology Index
BusinessWire - Wed Dec 16, 3:15PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of RNA interference (RNAi) therapeutics, today announced that the Company has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ:NBI), effective upon market open on December 21, 2015.
DRNA: 3.45 (-0.21)

Dicerna Pharmaceuticals Appoints John "Jack" Green Interim Chief Financial Officer
BusinessWire - Tue Dec 15, 5:54PM CST
Dicerna Pharmaceuticals, Inc. (NASDAQ

RNA), a leading developer of RNA interference (RNAi) therapeutics, today announced the appointment of John "Jack" Green as interim chief financial officer (CFO), effective January 1, 2016. He replaces James Dentzer, whose departure is also announced today.
VSTM: 1.44 (-0.07), DRNA: 3.45 (-0.21)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rachel Noble Joins AGS: Signals Strategy Shift

A Tactical Addition to American Global Strategies The chessboard of global security just saw a savvy new player join American Global Strategies (AGS). Rachel Noble, a name that echoes through the halls of Australia's national security apparatus, has joined AGS as Senior Advisor. This isn't your garden-variety hire—this is a strategic power move. From Down Under to the...

Boosting Employability: English Skills in Italy's Job Market

Tackling Language Barriers in Italy's Workforce If you're looking to make it big in Italy, you're facing a task that demands more than just regional expertise. The working world is no longer bound by borders, and for Italians eyeing international gigs, English fluency is a must-have. While not an absolute ticket to success, grasping English could be your career's booster...

Third Lake Parts Ways with WaterView Retail Center

Third Lake Partners Exits WaterView Retail in Florida Alright, you don't stumble across deals like this every day. Third Lake Partners just tossed the keys to their WaterView Retail Center in St. Petersburg, wrapping up the retail and residential parts under one roof with Walton Street Capital. It only took a cool five years since its completion in 2021, but hey, better...

Longevity Tour Hits East Coast: Brecka's Mission

Bringing Longevity to the East Coast This weekend, something interesting is happening on the East Coast of the U.S. Gary Brecka and his Ultimate Longevity Center (ULC) are holding a series of events in Philadelphia, New York, and Boston. Everything kicks off on November 14th. If the idea of 'live longevity' leaves you scratching your head, don’t worry—I've got you...

Abbisko's PIMJETMI® Gains FDA Nod, Boosting TGCT Treatment

PIMJETMI® Scores FDA Approval, Expanding Global Reach Well, here's something to chew on over your morning coffee—PIMJETMI® (pimicotinib) just snagged the U.S. FDA's blessing to treat tenosynovial giant cell tumor (TGCT), making it another notch on Abbisko Therapeutics' belt. This approval is a strategic home run for Abbisko and their pals at Merck KGaA, Darmstadt,...

Creative Solutions Joins FICO Marketplace, Boosts AI Edge

Creative Solutions and FICO Unite Well, we're diving into some strategic magic today. Creative Solutions International, not just your average marketing agency, has just hopped onto the FICO Marketplace platform. The word on the street is they're shaking things up with their Collections Marketing Platform. It's like giving your old financial letters a whole AI-driven paint...

Envista's $430M Senior Notes: A Market Move Decoded

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...

McEwen Faces Investigation Amid Declining Production

MUX Investors on Alert as Legal Stakes Rise The gold mining world isn't exactly flooded with excitement these days, and McEwen Inc.'s (NYSE: MUX) latest dealings ain't doing much to brighten up the scenery. When their third-quarter gold output took a nosedive—a 23% drop to be exact—it caught more eyes than a bull market will. Production Guidance in Question Now,...

Kemin Unveils LYSOFORTE ENFUSIO at EuroTier 2026

Rollin' up to EuroTier 2026 with all its buzz—a place where big players in livestock production flex their muscles—Kemin Industries dropped a new ace in the feed deck: LYSOFORTE ENFUSIO. They're betting this bad boy will shake things up for poultry and pig nutritionists looking to maximize what's already on their plate without piling on more grain or feed costs....

A Gentle Stake: Colts Neck's Rural Fight Ahead

By Ryan Hughes Updated Nov 10, 2026 Category News Views 101

Michael Fazio's Gambit in Colts Neck If you're not fired up about land deals, you should be now. Michael Fazio, the owner of Synergy Stables in Colts Neck, New Jersey, is laying his cards on the table with a proposition for preserving the integrity of the township's rural landscape. Rather than cashing in on monstrous offers for high-density housing, Fazio's plan involves...